On 18 November 2005, the U.S. Food and Drug Administration (FDA) alerted healthcare professionals and patients that several long-acting bronchodilator medicines have been associated with possible increased risk of worsening wheezing in some people, and requested that manufacturers update warnings in their existing product labeling. A 2006 meta-analysis found that "regularly inhaled β<unk> s (orciprenaline/metaproterenol Alupent, formoterol Foradil, fluticasone+salmeterol Serevent, Advair, and salbutamol/albuterol Proventil, Ventolin, Volmax, and others) increased the risk of respiratory death more than two-fold, compared with a placebo," while used to treat chronic obstructive pulmonary disease. On 11 December 2008, a panel of experts convened by the FDA voted to ban drugs Serevent and Foradil from use in the treatment of asthma. When these two drugs are used without steroids, they increase the risks of more severe attacks. They said that two other, much more popular, asthma drugs containing long-acting β<unk> s—Advair and Symbicort—should continue to be used.
Beta2-adrenergic agonist
Beta-adrenergic agonist
Alpha-adrenergic agonist
Muscarinic antagonist
Norepinephrine–dopamine disinhibitor
Dopamine agonist
Adrenergic release inhibitor
Adenosine receptor antagonist